Rosemary Mazanet

Rosemary Mazanet, M.D., Ph.D., is a member of the Board of Directors at Kainova Therapeutics. She brings more than two decades of experience across drug and clinical development, public equity investing, and strategic advisory roles, contributing to the company’s governance and portfolio oversight.

Dr. Mazanet is also a Venture Partner at Panacea Venture, a global life sciences investment firm focused on biopharmaceutical companies. Her work spans oncology, rare diseases, and novel therapeutic platforms, built on experience in clinical, industry, and investment settings.

Earlier in her career, Dr. Mazanet trained in Internal Medicine and Oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute before moving into industry, where she led clinical research at Amgen and directed development programs. She later moved into public equity as a partner at Oracle Partners, Apelles Investment Management, and Argenis Capital Advisors in New York, focusing on biotechnology and specialty pharma investments.

Dr. Mazanet also serves on the boards of several public, private, and commercial life sciences companies, bringing experience in governance, clinical-stage evaluation and portfolio management. She is an Emeritus Trustee at the University of Pennsylvania Health System and Chair of the External Advisory Board for the Wharton Leonard Davis Institute.

She holds an M.D. and a Ph.D. from the University of Pennsylvania.